Today's Rundown Roivant cuts staff, reassigns others in major reshuffle, as insider decries 'bloodbath' AbbVie and Calico renew their aging research collaboration with an extra $1B Precision BioSciences bags $110M to take off-the-shelf CAR-T into humans [Sponsored] The Growing Need for Data Management Solutions in Clinical Labs Dementia Discovery Fund reels in $350M for disease-modifying drugs Celgene inks $60M deal with newcomer Skyhawk to develop RNA drugs for ALS, Huntington’s Kaleido brings in $101M in series C for its microbiome-wide therapy pipeline BrainStorm backs down from providing ALS treatment under right-to-try Featured Story | | | Tuesday, June 26, 2018 Roivant has laid off some staff and reassigned others to subsidiaries in a notable strategic shift. The changes see Roivant shed around 10% of its staff and cede responsibility for others to the heads of its portfolio of startups. |
|
|
Top Stories Tuesday, June 26, 2018 AbbVie and Calico are reupping their massive, $1.5 billion research collaboration on age-related diseases first launched in 2014, with a new billion-dollar commitment split between the two. Tuesday, June 26, 2018 Precision BioSciences has raised $110 million. The series B round sets the genome editing specialist up to take its lead, off-the-shelf CAR-T therapy into clinical trials. Monday, June 25, 2018 The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need for simultaneous innovation in the technologies that enable that innovation and, likewise, the reliance on data management solutions that respond to an increasingly complex scientific environment. Monday, June 25, 2018 The Dementia Discovery Fund capped its fundraising at $350 million; it was nudged across the line by a $60 million investment from AARP. Tuesday, June 26, 2018 Celgene launched a $60 million collaboration with Skyhawk Therapeutics to develop and commercialize small molecules targeting RNA mis-splicing in neurological diseases. Monday, June 25, 2018 Kaleido Biosciences has raked in $101 million in series C financing, after coming out of stealth last September with $65 million, with the goal of developing novel chemistries that direct the human microbiome and its various bacteria as a whole. Tuesday, June 26, 2018 BrainStorm Cell Therapeutics has decided not to offer its experimental cell therapy for amyotrophic lateral sclerosis (ALS) under the newly passed law. The Israeli biotech considered ethical, legal and practical aspects of providing the treatment and said the clincher was its inability to fund the treatment for all patients who wanted to try it. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Innovation, Collaboration and Entrepreneurship in Drug Discovery June 28, 2018 | Cambridge, UK Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA RESI HealthTech Week September 5-7, 2018 | Boston, MA The 16th Annual Discovery on Target September 25-28, 2018 | Boston, MA FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA 10th International Leaders in Biobanking Congress October 14-16, 2018 | Cleveland, OH Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation | 